Skip Navigation

Center for Drug Safety and Effectiveness

Funded Research

Center faculty have active research portfolios, ranging from analyses of opioid abuse and diversion to the safety of new orally available anticoagulants to the development of innovative comparative effectiveness research methods.

The majority of the Center’s research funding is provided through grants from the Agency for Healthcare Research and Quality, the National Institutes of Health and other governmental and nonprofit sources. 

A select example of current or recently completed research projects is provided below.

Funding Source: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (R01DK120518)
Kidney transplantation (KT) is a growing treatment option for the >400,000 older adults (age ≥55) in the U.S. who suffer from end-stage renal disease (ESRD) and this population will rely on lifelong immunosuppression. The aim of this study is to quantify the differential effects of immunosuppression on cost-effectiveness, efficacy, morbidity, and mortality for older KT recipients and use this information to develop a risk calculator to help guide the choice of immunosuppression in older KT recipients.

Funding Source: National Institute on Aging (Desai-PI, Harvard)
This study seeks to evaluate the potential effectiveness of existing drugs for the prevention of Alzheimer’s disease using real-world data from multiple sources.

Funding Source: FDA (IBM Investigators- PI)
This project is working on developing automated methods for evaluating CBER-regulated products such as blood components and products derived from blood using data from the electronic health records.

Funding: Patient Centered Outcomes Research Institute Nelson (PI, University of Florida)
This is a large, pragmatic trial comparing new drugs for treatment of hepatitis C. Dr. Segal and colleagues at Hopkins are applying new methods to translate the trial results to populations who were not enrolled in the trial.